Medical University Of Silesia Katowice Poland

Research activity includes acute lymphoblastic leukaemia in children and adolescents, with interest in high-risk B-cell precursor ALL, genetic risk stratification, and treatment response-guided care. The sponsor is involved in studies addressing minimal residual disease and relapsed or refractory disease management.

• Childhood acute lymphoblastic leukaemia
• High-risk paediatric oncology
• Minimal residual disease
• Immunotherapy in leukaemia

Therapeutic interest extends to proteasome inhibition, antibody-based immunotherapy, and intrathecal methotrexate within collaborative paediatric cancer care.